Managing Cancer and Living Meaningfully (<scp>CALM</scp>) alleviates chemotherapy related cognitive impairment (<scp>CRCI</scp>) in breast cancer survivors: A pilot study based on resting‐state <scp>fMRI</scp>

Yao, Senbang; Zhu, Qing; Zhang, Qianqian; Cai, Yu; Shao-chun, Liu; Pang, Lulian; Jing, Yanyan; Yin, Xiangxiang; Huang, Cheng

doi:10.1002/cam4.6285

Cited by 2 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2) Task Selection Complexity: Employing tb-fMRI mandates the careful selection of the cognitive task to align precisely with the research objectives and to avoid unintended confounding factors in the results [43]. (3) Comparative Analysis: Utilizing rs-fMRI aligns with the existing research [44][45][46], which has employed rs-fMRI in the field of CRCI and mild cognitive impairment, enabling us to draw comparisons and contextualize our findings. In essence, the adoption of rs-fMRI was a strategic decision that accommodates the unique challenges posed by CRCI patients.…”

Section: Procedures and Data Analysesmentioning

confidence: 99%

Transcranial Magnetic Stimulation for the Treatment of Chemo Brain

Kuo,

Chen,

Rodriguez

et al. 2023

Sensors

View full text Add to dashboard Cite

This pilot feasibility study aimed to evaluate the effects of transcranial magnetic stimulation (TMS) on chemotherapy-related cognitive impairment (CRCI), and we report here on the first patient. Background: Deleterious cognitive changes due to chemotherapy or CRCI are commonly referred to as “chemo brain”. With the increasing survival of cancer patients, this poorly understood and inadequately treated condition will likewise have an increasing toll on individuals and society. Since there is no approved treatment for chemo brain, we have initiated a therapeutic trial using transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique approved in many countries for the treatment of neurologic and psychiatric conditions like migraine and depression. Case presentation: A 58-year-old woman, diagnosed 7 years prior with left breast cancer, underwent partial mastectomy with sentinel lymph node biopsy. She then received four cycles of adjuvant chemotherapy followed by radiation therapy. Afterwards, she was on tamoxifen for 4 years and then switched to aromatase inhibitors. The patient’s CRCI started during chemotherapy and severely impaired her quality of life for an additional two years. In the third year after chemotherapy, the CRCI partially cleared to stabilize to the level at the time of presentation for this trial. The patient continues to have memory difficulties and decreased concentration, which makes multi-tasking very difficult to impossible. She is reliant on memory aids at work and at home. The participant underwent 10 consecutive sessions of TMS during weekdays for 2 weeks. Stimulation was directed to the left dorsolateral prefrontal cortex. After TMS, the participant significantly improved in memory function on neuropsychological testing. While she reported no subjective differences in concentration or memory, she did report an improvement in her sleep. Functional magnetic resonance imaging of the brain before and after TMS showed increased resting-state functional connectivity between the stimulation site and several brain regions. Remarkably, after 6 years of chemo brain and remaining in the same position at work due to her inability to concentrate and multi-task, she applied for and received a promotion 5–6 months after her TMS treatments. Conclusions: This first patient in the phase 1 clinical trial testing of TMS for the treatment of “chemo brain” provided important lessons for feasibility and insights into mechanisms of potential benefit.

show abstract

Section: Procedures and Data Analysesmentioning

confidence: 99%

Transcranial Magnetic Stimulation for the Treatment of Chemo Brain

Kuo,

Chen,

Rodriguez

et al. 2023

Sensors

View full text Add to dashboard Cite

show abstract

“…Breast cancer is a major health concern for women, as it is the most prevalent type of cancer and the second leading cause of death among them. 1 , 2 In Iran, the age‐standardized incidence rate of breast cancer escalated from 18.8 per 100 000 in 1990 to 34.0 per 100 000 in 2019 among females and from 0.2 to 0.3 per 100 000 among males. 3 Advancements in oncology, surgery, and treatments such as radiotherapy, chemotherapy, and hormone therapy have significantly improved the survival rate of breast cancer patients, with over 90% surviving for 5 years.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, this systematic review aims to provide a comprehensive and up‐to‐date synthesis of the evidence on the specific effects of chemotherapy on the cognitive functions of breast cancer survivors. It will address the following research questions 1 : which domains or aspects of cognitive functions are most affected by chemotherapy? 2 how long does CRCI last after completing chemotherapy?…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy‐induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021

Amani,

Mazaheri,

Moghani

et al. 2024

Cancer Reports

View full text Add to dashboard Cite

BackgroundStudies have indicated that apart from enhancing patient survival, chemotherapy has adverse side effects on the psychological, social, and cognitive functions of breast cancer survivors.AimsThis study was conducted to understand chemotherapy's impact on breast cancer survivors' cognitive functions.Methods and ResultsOur study is a systematic review based on the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. We searched English databases, including PubMed/MEDLINE, PsycINFO, and Web of Science, and Persian databases, such as Irandoc and Elmnet, using Persian keywords of cancer, breast cancer, chemotherapy, cognitive functions, executive functions, and neuropsychological functions. Two reviewers independently evaluated the full text of the articles according to predefined criteria. Among the 937 available studies, 26 were selected based on the inclusion and exclusion criteria, of which 17 (65%) were longitudinal and 9 (35%) were cross‐sectional. The findings indicated a significant relationship between the use of chemotherapy and cognitive impairments, most notably attention, working and short‐term memory, and executive functions. However, the studies differed in their findings regarding the long‐term persistence of cancer‐related cognitive impairment (CRCI), which could be due to the wide range of tools used, different methods to measure cognitive functions, and the difference in the sample size of the studies.ConclusionChemotherapy, affecting cortical and subcortical brain structures, causes a set of cognitive impairments that can lead to impairments in social responsibility acceptance, daily functioning, and quality of life of women. Therefore, rigorous and extensive research design is required to understand the causes and consequences of CRCI using standardized and sensitive measures of cognitive functions. Specifically, studies comparing the effects of different chemotherapy regimens on cognition and potential mechanisms and/or moderators of CRCI would be instrumental in designing more effective therapy regimens and evaluating the efficacy and cost‐effectiveness of cognitive rehabilitation and supportive care programs.

show abstract

Managing Cancer and Living Meaningfully (CALM) alleviates chemotherapy related cognitive impairment (CRCI) in breast cancer survivors: A pilot study based on resting‐state fMRI

Cited by 2 publications

References 55 publications

Transcranial Magnetic Stimulation for the Treatment of Chemo Brain

Transcranial Magnetic Stimulation for the Treatment of Chemo Brain

Chemotherapy‐induced cognitive impairment in breast cancer survivors: A systematic review of studies from 2000 to 2021

Contact Info

Product

Resources

About